Analgesic Effect of a Biophotonic Foot Massage Cream (No acronym)

Analgesic Effect of a Biophotonic Foot Massage Cream: A Randomized Clinical Trial

This study aims to evaluate the effectiveness of a biophotonic cosmetic massage cream in reducing musculoskeletal foot pain in adults. Participants with pain in one or both feet attending the Podiatry Clinical Area of the University of Seville will be randomly assigned to receive either the investigational cream or a placebo cream with similar characteristics. The assigned product will be applied topically to the painful area twice daily for 10 consecutive days. Pain intensity, pressure pain threshold, foot function, and health-related quality of life will be assessed during the study.

Study Overview

• Status: Not yet recruiting
• Conditions: Musculoskeletal Pain
• Intervention / Treatment: Other: Biophotonic cosmetic massage cream; Other: Placebo

Detailed Description

Foot pain is a common and clinically relevant problem in adults, and musculoskeletal foot pain is frequently managed with oral and topical pharmacological treatments. However, conventional analgesic and anti-inflammatory therapies may be associated with adverse effects, which supports the investigation of potentially safer conservative alternatives. This study is designed as a randomized, placebo-controlled, parallel-group clinical trial to assess whether a biophotonic cosmetic massage cream can significantly reduce musculoskeletal foot pain in adults.

Eligible participants will be adults with musculoskeletal pain in one or both feet who attend the Podiatry Clinical Area of the University of Seville. Participants will be recruited consecutively in the context of routine clinical care and will be randomly assigned in a 1:1 ratio to either an experimental group receiving the biophotonic cosmetic massage cream or a control group receiving a placebo with similar characteristics.

The intervention consists of topical self-application of the assigned product to the painful area of the foot twice daily for 10 consecutive days, following instructions provided by the research team. The primary outcome will be pain intensity measured using the Numeric Pain Rating Scale (NPRS-11). Secondary outcomes will include pressure pain threshold measured with a Wagner FPK 10 pressure algometer, foot pain and function assessed with the Foot Function Index, and health-related quality of life assessed with the SF-12 questionnaire.

The planned sample size is 170 participants, corresponding to 85 per group, allowing for an anticipated 20% loss to follow-up. Statistical analyses will compare changes between groups and over time, with a significance level of 0.05 and analysis preferably following the intention-to-treat principle.

• Study Type: Interventional
• Enrollment (Estimated): 170
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Pedro Vicente Munuera-Martínez, Ph.D; Phone Number: +34696437996; Email: pmunuera@us.es

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adults aged 18 years or older.
• Patients attending the Podiatry Clinical Area of the University of Seville.
• Presence of musculoskeletal pain in one or both feet at the initial assessment.
• Ability to understand the study information and provide written informed consent.
• Ability to follow study instructions and complete study assessments.
• Intact skin at the application site.

Exclusion Criteria:

• Foot pain of non-musculoskeletal origin, or pain mainly attributable to infectious, vascular, tumoral, severe neurological, or decompensated systemic diseases.
• Wounds, ulcers, burns, dermatitis, skin infections, or any active skin disorder at the application site.
• Known allergy, hypersensitivity, or previous adverse reaction to any component of the investigational cream or placebo.
• Concomitant use of analgesic, anti-inflammatory, or topical treatments on the foot that may interfere with efficacy assessment, unless a washout period is established.
• Recent infiltrations, surgery, or invasive treatment on the foot or ankle that may alter pain evolution during the study.
• Pregnancy or breastfeeding.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Biophotonic cosmetic massage cream	Other: Biophotonic cosmetic massage cream; Topical self-application of the investigational cosmetic massage cream to the painful area of the foot, twice daily for 10 consecutive days, according to the instructions provided by the research team.
Placebo Comparator: Placebo; Topical self-application of the placebo cream to the painful area of the foot, twice daily for 10 consecutive days, according to the instructions provided by the research team.	Other: Placebo; Topical self-application of the placebo cream to the painful area of the foot, twice daily for 10 consecutive days, according to the instructions provided by the research team.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in pain intensity measured with the Numeric Pain Rating Scale (NPRS-11)	Pain intensity will be assessed using the Numeric Pain Rating Scale (NPRS-11), which minimum value is 0 (that means no pain, the best result) and maximum value is 10 (that means the worst pain the participant could withstand). The primary endpoint will be the change in pain score from baseline to the end of the 10-day intervention period.	Baseline to Day 10

Collaborators and Investigators

• Sponsor: University of Seville

Study record dates

Study Major Dates

• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): September 1, 2027

Study Registration Dates

• First Submitted: March 24, 2026
• First Submitted That Met QC Criteria: March 24, 2026
• First Posted (Actual): March 30, 2026

Study Record Updates

• Last Update Posted (Actual): April 2, 2026
• Last Update Submitted That Met QC Criteria: March 28, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Randomized clinical trial; Placebo; Musculoskeletal pain; Topical treatment; Podiatry; Foot pain; Biophotonic cream
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Musculoskeletal Diseases; Muscular Diseases; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Musculoskeletal Pain
• Other Study ID Numbers: BEIMAN_PIE

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No